Date: December 19th, 2016

Professor David Barlow - Chair of Hamad Medical Corporation IRB
Dr. Rusung Tan - Chair of Sidra Medical and Research Center IRB
Dr. Ziyad Hijazi - Principal Investigator

This letter is in reference to the clinical trial titled "Implantation of the Venus P Valve in the Pulmonic Position in Patients with Native Outflow Tracts", submitted on November 13th, 2016 by Hamad Medical Corporation.

The study is sponsored by Venus Medtech Inc.

Research proposal	Reviewed Document
16365/15	1) 15365_ Protocol_VQatar_Eng_Oct16_60Pages 2) 15365_InformedConsent_Eng-Ara_05Oct16_13Pages 3) 15365_CRF_Eng_27Apr16_27Pages 4) 15365_DSMB_v1.1_9Jul15_175Pages 5) 15365_Investigationbrochure_V1.5_3May13_32Pages 6) 15365_SchemeOfDelegation_02Pages

Upon review of the submitted documents, the Ministry of Public Health (MoPH) supports the conduct of this clinical trial with the need to establish a Data and Safety Monitoring Board (DSMB) committee. Please be noted that it is the institution, sponsor and the Principal Investigator (PI)'s responsibility, to ensure that this clinical trial is conducted in compliance with MoPH regulations and the principles of International Conference of Harmonization (ICH) - Good Clinical Practice (GCP), and to ensure the below responsibilities are fulfilled:

Dr. Ziyad Hijazi's responsibility

1. The safety and wellbeing of participants are protected
2. The research is conducted in accordance with the local IRB-approved protocol, including the approved recruitment and consent procedures
3. Informed Consent is obtained and documented before research participation begins
4. All unanticipated problems, including adverse event(s) are reported in accordance with the IRB's policy and the ministry reporting of adverse events.
5. The protocol's amendments (e.g., protocol, recruitment materials, consent form, status of the study, etc.) is submitted to the IRB for review and approval prior to initiation of the change(s), except where necessary to eliminate hazards to the subject(s). Changes made to eliminate apparent immediate hazards to subjects must be reported to the IRB as unanticipated problem

6. All investigators and study staff listed on the project are informed of changes and unanticipated problems, including adverse events, involving risks to subjects or others

7. The continuing review submission to the IRB should be submitted with sufficient time to allow for IRB review and approval and provide an opportunity for response by the Principal Investigator to any stipulations of the local registered IRB

8. When the research protocol ends, a final report is submitted to the IRB

9. Adequate and accurate research records are kept and retained

10. The confidentiality of data is maintained at all times

11. Upon request for monitoring and oversight of the research, research records are made available to MoPH, the DSMB, the sponsor

12. all medical devices logistic is maintained and recorded

13. When supervising the conduct of the research, the PI ensures that study personnel:

- are qualified by training and experience, and credentialed if necessary, to perform study-related tasks that have been assigned to them.
- are aware of regulatory and policy requirements and standards for the conduct of human subjects research.
- have a complete understanding of the details of the protocol relevant to the tasks they will be performing.
- Follow the IRB-approved protocol.
- are informed of any pertinent changes to the protocol during the conduct of the study and are educated or given additional training, as appropriate

- **It is the IRBs' (both HMC and Sidra) responsibility to:**

1. Monitor the safety and wellbeing of research participants
2. Ensure that informed consents are in place
3. Provide enough support to the PI to fulfill his above mentioned responsibilities
4. Protect the privacy and confidentiality of participants.
5. Provide one to one training to involved research staff.
6. Conduct periodic reviews throughout the trial's duration.
7. Conduct continuous monitoring during the conduct of the trials.
8. Report all unanticipated problems including adverse events to the MoPH.
9. Keep IRB meeting minutes, trial recordkeeping, etc. for inspection purposes.
10. Monitor the work conducted by the Data and Safety Monitoring Board.

- **It is the Sidra Data and Safety Monitoring Board registered under the registration number MOPH-SIDRA-DSMB-002 responsibility to:**

1. Periodically review and evaluate the accumulated study data for participant safety, study conduct and progress, and, when appropriate, efficacy.
2. Make recommendations concerning the continuation, modification, or termination of the trial.
3. Ensure that the timeliness, completeness, and accuracy of the data submitted to them for review are sufficient for evaluation of the safety and welfare of study participants.
4. Report adverse events to the collaborative IRBs, the sponsor, and MoPH.

For any enquiries, please contact the Research Department via: irb@moph.gov.qa

Sincerely yours,

Dr. Eman Sadoun
dresadoun@moph.gov.qa
Manager, Human Research
Ministry of Public Health
T: 4407-036